Brief: Zoetis Receives European Commission Marketing Authorization For Lenivia (Izenivetmab) To Reduce Pain Associated With Osteoarthritis (OA) In Dogs
26/11/2025 21:17
Nov 26 (Reuters) - Zoetis Inc ZTS.N: ZOETIS RECEIVES EUROPEAN COMMISSION MARKETING AUTHORIZATION FOR LENIVIA® (IZENIVETMAB) TO REDUCE PAIN ASSOCIATED WITH OSTEOARTHRITIS (OA) IN DOGS Source text: ID:nBw8nv7BLa Further company coverage: ZTS.N ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Zoetis
See all newsBrief: Zoetis Receives FDA Approval For Convenia® Rtu For Dogs (Cefovecin Injectable Suspension), Helping More Medium And Large Dogs Access Single-Injection Treatment
Brief: FDA Approves Ready-To-Use Cefovecin Injectable For Treatment Of Certain Skin Infections In Dogs
U.S. RESEARCH ROUNDUP-Masco, Sherwin-Williams, Vulcan Materials
Zoetis gets US FDA emergency use nod for treatment for screwworm in dogs
Brief: FDA Issues Emergency Use Authorization For Simparica Trio To Treat New World Screwworm In Dogs, Puppies